Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy as neoadjuvant treatment for gastroesophageal junction adenocarcinoma
ChiCTR2300068184Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in gastroesophageal junction adenocarcinoma and esophagogastric junction cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological complete remission rate. Started Sep 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastroesophageal junction adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2300068184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068184.